Apotex Pty Ltd v Warner Chilcott Company, LLC

Link copied
Case Copied 23 min read

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Apotex Pty Ltd v Warner Chilcott Company, LLC [2016] APO 29

Patent Application:                   2011218625

Title:Dosage forms of risedronate

Patent Applicant:  Warner Chilcott Company, LLC          

Opponent:  Apotex Pty Ltd

Delegate:  K. Wagg

Decision Date:  23 May 2016

Hearing Date:  1 March 2016

Catchwords:  PATENTS – Opposition unsuccessful–claims are novel and inventive because the cited prior art teaches away from the opposed claims–Costs awarded against the opponent.

Representation:  Patent Applicant:  Ben Fitzpatrick of Counsel instructed by David Miles and Bernard Nutt of Pizzeys            

Opponent:Craig Smith of Counsel instructed by James Cherry and Sarah Hennebry of Freehills

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Patent Application:                   2011218625

Title:Dosage forms of risedronate    

Patent Applicant:  Warner Chilcott Company, LLC

Date of Decision:  23 May 2016

DECISION

The opposition fails.

Subject to appeal, patent applicant number 2011218625 is to proceed to grant.

I award costs according to Schedule 8 against Apotex Pty Ltd.

REASONS FOR DECISION

  1. Patent application number 2011218625 (the opposed application) was filed on 29 August 2011.  It is a divisional of application number 2005330654 (the parent application), now withdrawn.  The Applicant is Warner Chilcott Company, LLC (the Applicant). The application was examined by the Commissioner and acceptance was advertised on 20 March 2014.  On 20 June 2014, Apotex Pty Ltd (the Opponent) filed a Notice of Opposition.  

  2. A hearing was held on 1 March 2016 in Canberra to decide the opposition.  The Applicant was represented by Ben Fitzpatrick of Counsel instructed by David Miles and Bernard Nutt of Pizzeys.  The Opponent was represented by Craig Smith of Counsel instructed by James Cherry and Sarah Hennebry of Freehills.

  3. The request for examination was filed prior to 15 April 2013. As a consequence, substantive amendments of the Patents Act 1990 brought about by the Intellectual Property Laws Amendment (Raising the Bar) Act 2012 do not apply to the present patent application. This includes the amendment to subsection 60 (3A) that allows the Commissioner to refuse a patent application if satisfied on the balance of probabilities that a ground of opposition exists. I also note that any subsequent reference to the Patents Act relates to the Patents Act1990 (the Act), prior to amendment by the Intellectual Property Laws Amendment (Raising the Bar) Act 2012.

    Standard of proof

  4. The onus of proof in this opposition proceeding rests with the Opponent, who must demonstrate that it is clear that a valid patent cannot be granted (F.Hoffman-La Roche AG v New England Biolabs Inc [2000] FCA 283 at [67]; 50 IPR 305; Commissioner of Patents v Sherman [2008] FCAFC 182 at [18]; 79 IPR 426).

    The opposition

  5. The Statement of Grounds and Particulars identified seven grounds of opposition.  At the hearing, the opposition was limited to the grounds of novelty and inventive step.

  6. The parties relied upon evidence by several declarants.  Evidence in support is as follows:

Evidence in Support
Date of declaration Declarant Annexes Abbreviation
23 October  2014 Robert William Milne
CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Apotex Pty Ltd v Warner Chilcott Company, LLC and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2016] APO 29
Decision Date

CaseChat Overview and Summary

Apotex Pty Ltd opposed the grant of patent application number 2011218625 (the opposed application) to Warner Chilcott Company, LLC. The invention related to oral dosage forms of risedronate, a compound used in the treatment of conditions involving abnormal calcium and phosphate metabolism. The invention involved a pharmaceutical composition containing risedronate, a chelating agent, and a means for effecting delayed release of risedronate and the chelating agent in the small intestine. The opposed application was a divisional of application number 2005330654 (the parent application), which had been withdrawn. The Opposition was heard on 1 March 2016 in Canberra. The Opponent limited its opposition to the grounds of novelty and inventive step. The Applicant responded to the opposition and filed Evidence in Answer. The Opponent then filed Evidence in Reply. The Delegate found that the opposed application was novel and inventive. The Delegate concluded that the opposition was not successful. Subject to appeal, patent applicant number 2011218625 is to proceed to grant. The Delegate awarded costs against the Opponent.

Background

Background to the litigation

Patent application 2011218625, filed by Warner Chilcott Company, LLC, relates to oral dosage forms of risedronate, a bisphosphonate used for treating conditions involving abnormal calcium and phosphate metabolism. The specification outlines a need for an oral dosage form of a bisphosphonate that can be taken with or without food or beverages, without causing upper gastrointestinal irritation, and which achieves pharmaceutically effective absorption. The invention comprises a pharmaceutical composition containing risedronate, a chelating agent like EDTA, and a delayed release mechanism to release the components in the small intestine. Independent claims 1 and 28 specify the composition's components and dosages, with claim 1 detailing about 35 mg of risedronate and 100 mg of EDTA, and claim 28 detailing about 150 mg of a bisphosphonate selected from risedronate and 55 mg to 500 mg of EDTA. The claims also include a delayed release mechanism to deliver the components to the lower gastrointestinal tract.

The matter came before the Australian Patent Office as an opposition to the patent application filed by Apotex Pty Ltd on 20 June 2014. The opposition was limited to the grounds of novelty and inventive step. A hearing was held on 1 March 2016 in Canberra. Warner Chilcott Company, LLC, the patent applicant, was represented by Ben Fitzpatrick of Counsel, and Apotex Pty Ltd, the opponent, was represented by Craig Smith of Counsel. The decision, rendered on 23 May 2016, dismissed the opposition, allowing the patent application to proceed to grant, and awarded costs against Apotex Pty Ltd.

Decision

Reasons for decision

Issues
1. Does the prior art document BR 0106601-3 A (LIBBS PHARMACEUTICAL COMPANY LTDA.) anticipate the claims of the opposed application?
2. Does the combination of the prior art document BR 0106601-3 A and common general knowledge render the claims of the opposed application obvious?

Held
1. The opposition against patent application number 2011218625 is unsuccessful on both grounds of novelty and inventive step.
2. Subject to appeal, patent applicant number 2011218625 is to proceed to grant.
3. Costs are awarded according to Schedule 8 against Apotex Pty Ltd.

Ratio Decidendi

Legal Principle Established

The Delegate of the Commissioner of Patents, K. Wagg, considered the grounds of opposition regarding the novelty and inventive step of the opposed application. In terms of novelty, the Delegate found that BR 0106601-3 A (LIBBS PHARMACEUTICAL COMPANY LTDA.) did not anticipate the claims of the opposed application because it did not provide clear and unmistakable directions for the specific dosages of risedronate required by the claims. Although BR '601 disclosed the use of risedronate, it did not specify the dosages of risedronate that are essential to the invention as claimed in the opposed application.

Regarding the inventive step, the Delegate determined that the combination of BR '601 and common general knowledge would not have led the person skilled in the art to the opposed application as a matter of routine. The document BR '601 taught using lower quantities of bisphosphonate compared to the standard doses available at the priority date, and the evidence did not demonstrate that it would be routine to disregard this teaching and use the standard doses.

The Delegate concluded that the opposition was unsuccessful on both grounds of novelty and inventive step, and therefore, the patent application number 2011218625 is to proceed to grant, subject to appeal. Costs were awarded to the patent applicant, Warner Chilcott Company, LLC, against the opponent, Apotex Pty Ltd.